decrease the likelihood of discovering unknown toxic effects in larger populations and costly phase 2 and 3 studies. That (2) prospectively delineating therapeutic intent with prespecified clinical end points should be adopted because it may facilitate early identification of efficacy and improve insurance coverage of and patient access to early-phase trials.
Chemotherapy-Related Chronic Myelogenous Leukemia: A Case Series of Patients With Germ Cell Tumor
Germ cell tumors (GCTs) are the most common cancer in young men ages 15 to 35 years and are uniquely responsive to chemotherapy, with cure rates approaching 80%. Late adverse effects of treatment can manifest throughout the lifetime of a cured patient who will be at increased risk of solid and hematologic malignant neoplasms.
1,2 Etoposide has become one of the cornerstones of platinum-containing regimens for GCT. Treatment with etoposide entails a known risk of secondary leukemia that typically exhibits a short latency period, a chromosomal translocation (11q23 and 21q22), and rearrangement of the mixed-lineage leukemia gene.
Methods | We observed 3 patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) following therapy for GCT.
Results | Case 1. In 1999, a man in his mid-30s with nonseminomatous GCT (NSGCT) was treated with orchiectomy followed by 4 courses of bleomycin, etoposide, and cisplatin. In September 2011, he was noted to have a white blood cell count (WBC) of 111 700/μL (111.7 × 10 9 /L). Bone marrow examination showed morphologic findings of chronic-phase CML, and a t(9;22)(q34;q11) was identified. The patient started treatment with imatinib and achieved a complete molecular remission. Unfortunately, in 2014, he developed malignant transformation of teratoma to an undifferentiated neuroendocrine carcinoma with unresectable hepatic metastases and died of his disease.
Case 2. In 2006, a man in his early 30s had orchiectomy for clinical stage I NSGCT and elected to receive a single cycle of BEP. In November 2006, the disease relapsed, and he was treated with 3 cycles of etoposide, ifosfamide, and cisplatin (VIP). In 2007, the patient experienced a second relapse and was treated with 2 cycles of high-dose carboplatin and etoposide followed by peripheral blood stem cell rescue. In 2011, he was found to have leukocytosis (WBC, 91 700/μL [91.7 × 10 9 / L]). Bone marrow examination confirmed chronic-phase CML with t(9;22)(q34;q11). The patient was treated with dasatinib and achieved a molecular remission . To date, he continues to be in remission for his CML and recurrent GCT. L]). Bone marrow examination confirmed chronic-phase CML by morphologic characteristics, and a t(9;22)(q34;q11) was identified by chromosome analysis. The patient started treatment with dasatinib and achieved a hematologic response. To date, his BCR/ABL transcript declined appropriately from 55% to 9%. He continues to be in remission for his GCT.
Discussion | There have been reports of chemotherapy-related Philadelphia-chromosome leukemias in patients with antecedent malignant neoplasms. 3 Past treatments for GCT with cisplatin-etoposide-containing regimens or HDCT with carboplatin-etoposide have been linked to an increased risk of secondary acute leukemia 1,4 and solid tumors. 5 A review of the literature reveals 7 cases of GCT with subsequent development of CML. 1, 3, 6 In this series, we present 3 cases of patients with GCT who achieved remission with chemotherapy and later developed BCR/ABL-positive CML. These findings raise the question of a causal relationship between etoposide and/or platinum-containing chemotherapy and the development of CML with t(9;22)(q34;q11). Etoposide-based chemotherapy in patients with GCT is leukemogenic. It is not clear whether combination chemotherapy with cisplatin and bleomycin contribute to this result. While its association with AML is well established, questions regarding the connection of etoposide and cisplatincontaining combination chemotherapy and secondary CML are posed herein. The relatively low risk of secondary leukemia in patients treated with potentially curative combination chemotherapy for GCT continues to be reassuring. 1 However, physicians should be aware of possible late toxic effects of these treatment regimens and the need for diligent follow-up in these patients.
